Alpha 2.0
Login Register
» Articles » PMID: 18521597

Prostate Biopsy Guided by 18F-fluorocholine PET in Men with Persistently Elevated PSA Levels

Overview
Journal Eur J Nucl Med Mol Imaging
Specialties Biophysics
Nuclear Medicine
Radiology
Date 2008 Jun 4
PMID 18521597
Citations 13
Authors
Sandi A Kwee
Tim DeGrado
Affiliations
Soon will be listed here.
Citing Articles

F-18 fluorocholine positron emission tomography- computed tomography in initial staging and recurrence evaluation of prostate carcinoma: A prospective comparative study with diffusion-weighted magnetic resonance imaging and whole-body skeletal....

Vatsa R, Kumar R, Shukla J, Rana N, Vadi S, Lal A World J Nucl Med. 2021; 20(2):156-163.

PMID: 34321968 PMC: 8286002. DOI: 10.4103/wjnm.WJNM_46_20.

Detection rates of recurrent prostate cancer: Gallium (Ga)-labelled prostate-specific membrane antigen choline PET/CT scans. A systematic review.

Moghul M, Somani B, Lane T, Vasdev N, Chaplin B, Peedell C Ther Adv Urol. 2019; 11:1756287218815793.

PMID: 30671137 PMC: 6329022. DOI: 10.1177/1756287218815793.

Ga-PSMA and C-Choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle.

Alonso O, Dos Santos G, Garcia Fontes M, Balter H, Engler H Eur J Hybrid Imaging. 2018; 2(1):9.

PMID: 29782606 PMC: 5954786. DOI: 10.1186/s41824-018-0027-1.

Diagnostic performance of Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with FEC PET/CT.

Hoffmann M, Miederer M, Wieler H, Ruf C, Jakobs F, Schreckenberger M Oncotarget. 2018; 8(67):111073-111083.

PMID: 29340038 PMC: 5762306. DOI: 10.18632/oncotarget.22441.

Molecular imaging and fusion targeted biopsy of the prostate.

Fei B, Nieh P, Master V, Zhang Y, Osunkoya A, Schuster D Clin Transl Imaging. 2017; 5(1):29-43.

PMID: 28971090 PMC: 5621648. DOI: 10.1007/s40336-016-0214-7.

References
1.
Rietbergen J, Kruger A, Hoedemaeker R, Bangma C, Kirkels W, Schroder F . Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol. 1998; 160(6 Pt 1):2121-5. DOI: 10.1097/00005392-199812010-00046. View
2.
Kwee S, Coel M, Lim J, Ko J . Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2004; 173(1):252-5. DOI: 10.1097/01.ju.0000142099.80156.85. View
3.
Wefer A, Hricak H, Vigneron D, Coakley F, Lu Y, Wefer J . Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000; 164(2):400-4. View
4.
Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K . Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001; 49(4):243-50. DOI: 10.1002/pros.10019. View
5.
Igerc I, Kohlfurst S, Gallowitsch H, Matschnig S, Kresnik E, Gomez-Segovia I . The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35(5):976-83. DOI: 10.1007/s00259-007-0686-9. View